Navigation Links
Inaugural Herbert A. Fleisch ESCEO-IOF Medal is awarded to Professor Gerard Karsenty
Date:3/9/2011

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF) have announced that Professor Gerard Karsenty of the Columbia University Medical Center is to be awarded the first Herbert A. Fleisch ESCEO-IOF Medal. Herbert Fleisch was a renowned researcher whose groundbreaking work contributed to the development of the field of scientific knowledge about metabolic bone diseases and their treatment.

The newly created award, valued at 20,000 Euro, recognizes a researcher who has made outstanding and groundbreaking achievements in basic bone science. The Medal will be presented on March 23rd at an award ceremony to take place at the opening of the European Congress on Osteoporosis & Osteoarthritis (ECCEO11-IOF), in Valencia, Spain.

Gerard Karsenty M.D., Ph.D., is Professor and Chair, Department of Genetics & Development, at the Columbia University Medical Center, New York. Professor Karsenty is renowned for his many fundamental contributions to understanding skeletal development and skeletal physiology. His laboratory has been instrumental in identifying Runx2 as the master gene of osteoblast differentiation and in deciphering the entire genetic cascade of osteoblast differentiation. He has contributed to the molecular elucidation of bone mineralization and has made significant advances in the study of bone physiology, based on the hypothesis he proposed that there must be a common control of bone mass, energy metabolism and reproduction. Testing this hypothesis revealed the existence of a central control of bone mass, a function regulated by leptin, a hormone appearing during evolution with bone cells and that inhibits both appetite and bone mass accrual. His laboratory then showed that bone is itself an endocrine organ producing an hormone, osteocalcin, that favors glucose homeostasis and male reproduction. Lastly Dr. Karsentys lab has shown that gut-derived serotonin is a powerful inhibitor of bone formation.

"Gerard Karsenty has been one of the most creative minds in the bone field, making exciting new findings that have furthered our understanding of skeletal physiology and the mechanisms of bone formation, said Professor Jean-Yves Reginster, President of ESCEO.

IOF President John Kanis went on to state, "This award, named in honour of a pioneer in osteoporosis research, appropriately recognizes an individual whose work has considerably influenced knowledge about bone and mineral metabolism."

Professor Karsenty has received a number of honours and awards, including the Lee C. Howley Prize for Arthritis Research in 2008. He is the Chair of the upcoming 1st IOF-ESCEO Pre-Clinical Symposium, to be held in Valencia from March 22-23, 2011.


'/>"/>

Contact: L. Misteli
info@iofbonehealth.org
International Osteoporosis Foundation
Source:Eurekalert

Related biology news :

1. International AIDS Society announces inaugural recipients of innovative HIV research awards
2. George Whitesides accepts inaugural Dreyfus Prize in the Chemical Sciences
3. George M. Whitesides receives inaugural Dreyfus prize in the chemical sciences
4. Easton honored with inaugural AACR Outstanding Investigator Award in Breast Cancer Research
5. Massague honored with inaugural AACR Distinguished Leadership Award in Breast Cancer Research
6. Penn presents inaugural symposium on applied mathematics and computational science
7. Dr. George Stark receives 2011 Herbert Tabor/Journal of Biological Chemistry Lectureship from ASBMB
8. Nobel laureate claims the 2010 Herbert Tabor Lectureship
9. ESCEO-IOF-ABBH Young Investigator Awards recognize research excellence
10. Genetic studies of human evolution win researcher 2011 Gani Medal
11. NIMHs Dr. Mortimer Mishkin to be awarded National Medal of Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology: